iCAD (NASDAQ:ICAD) Upgraded at StockNews.com

iCAD (NASDAQ:ICAD) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Wednesday.

iCAD Stock Performance

NASDAQ ICAD opened at $2.27 on Wednesday. iCAD has a fifty-two week low of $1.18 and a fifty-two week high of $3.78. The stock has a market cap of $60.25 million, a PE ratio of -17.46 and a beta of 1.95. The firm’s fifty day moving average price is $2.67 and its two-hundred day moving average price is $2.08.

iCAD (NASDAQ:ICAD) last issued its earnings results on Wednesday, March 19th. The technology company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.02. iCAD had a negative return on equity of 15.65% and a negative net margin of 17.81%. The business had revenue of $5.41 million during the quarter, compared to analysts’ expectations of $4.72 million.

Institutional Investors Weigh In On iCAD

A number of institutional investors have recently added to or reduced their stakes in the business. waypoint wealth counsel grew its position in shares of iCAD by 44.0% in the 4th quarter. waypoint wealth counsel now owns 14,400 shares of the technology company’s stock valued at $26,000 after buying an additional 4,400 shares during the last quarter. Thompson Davis & CO. Inc. bought a new stake in iCAD in the fourth quarter valued at approximately $31,000. PKS Advisory Services LLC bought a new stake in iCAD in the fourth quarter valued at approximately $53,000. Wells Fargo & Company MN increased its position in iCAD by 51.3% during the 4th quarter. Wells Fargo & Company MN now owns 39,542 shares of the technology company’s stock valued at $72,000 after purchasing an additional 13,402 shares during the period. Finally, Integrated Wealth Concepts LLC bought a new position in iCAD during the 4th quarter worth approximately $92,000. 24.61% of the stock is owned by institutional investors.

About iCAD

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.